Peg Interferon α-2b for Relapsed Hematological Malignancies After

Status Completed

Clinical Trial Summary

Aim: to observe the graft versus tumor effect of Pegylated Interferonα-2b in patients with hematological malignancies relapsed after allogeneic hematopoietic stem cell transplantation (alloHSCT) Patients: patients relapsed after alloHSCT, men and women aged 14-60 years, without vital organ dysfunction or ongoing graft-verus-host disease (GVHD). Number of subjects: 50, Single center, one group, prospective. Drug: pegylated interferon alpha-2b (Peg Intron®; Schering-Plough) 1~1.5ug/kg qw, until occurrence of grade II or higher grade of acute GVHD, or no response to treatment after 8 doses of treatments.

Clinical Trial Description

Eligible patients were age 14 to 60 years with molecular, hematological or radiography relapsed hematological malignancies post allogeneic hematopoietic stem cell transplantation. Molecular relapse was defined as reappearance or 1 log increase of molecular markers or decreasing donor chimerism by more than 5%; Hematological relapse was defined as reappearance of blast in bone marrow smear by more than 5%; radiography relapse was defined as enlargement of lymph nodes by more than 25% or infiltration of tumor cells in other sites. Patients were excluded if they need immunosuppressant treatment for ongoing grade II～IV acute GVHD or moderate to severe chronic GVHD. Eligible patients were treated with pegylated interferon alpha-2b (Peg Intron®; Schering-Plough (Brinny) Company, Innishannon, County Cork, Ireland) 1~1.5ug/kg qw, until occurrence of grade II or higher grade of acute GVHD, or no response to treatment after 8 doses of treatments. Patients were followed up every week. Physical exams and blood tests including complete blood count (CBC), chemical were performed every week. Disease status evaluation was performed every month. Number of subjects: 50 Single center, one group, prospective. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02634294
Study type	Interventional
Source	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Contact
Status	Completed
Phase	Phase 2/Phase 3
Start date	August 2015
Completion date	December 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03545659` - Childhood Acute Lymphoblastic Leukaemia: Follow-Up
Completed	`NCT04838613` - Study of Diagnostic Performance of [18F]CTT1057 in BCR	Phase 3
Recruiting	`NCT05233020` - Robotic Versus Hybrid Assisted Ventral Hernia Repair	N/A
Recruiting	`NCT04539665` - Extended Mesenteric Excision in Ileocolic Resections for Crohn's Disease.	N/A
Recruiting	`NCT04266600` - Extended Mesenteric Excision in Ileocolic Resections for Crohn's Disease	N/A
Terminated	`NCT03257722` - Pembrolizumab + Idelalisib for Lung Cancer Study	Phase 1/Phase 2
Completed	`NCT01141335` - Polypropylene Mesh Versus Polytetrafluoroethylene (PTFE) Mesh in Inguinal Hernia Repair	Phase 4
Completed	`NCT00029185` - Study of Dehydrex in Patients With Corneal Erosion	N/A
Completed	`NCT01351974` - Sentinel Node Biopsy in Breast Cancer Patients	N/A
Not yet recruiting	`NCT06038422` - GTP Regimen in the Treatment of Refractory/Recurrent HLH	Phase 3
Withdrawn	`NCT03162120` - Comparison of Effectiveness of Ranolazine Plus Metoprolol Combination vs. FlecainidE pluS Metoprolol Combination in ATrial Fibrillation Recurrences FOllowing PhaRmacological or Electrical CardioverSion of AtRial Fibrillation	Phase 2/Phase 3
Recruiting	`NCT04159051` - Charité HT-Prostate	N/A
Recruiting	`NCT02566928` - Patient-Centered Comparative Effectiveness Research (CER) Study of Home-based Interventions to Prevent CA-MRSA Infection Recurrence	Phase 4
Completed	`NCT01989845` - Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer	Phase 4
Recruiting	`NCT01229475` - Stepwise Approach Versus Linear Ablation in Patients With Recurrence of Persistent Atrial Fibrillation	N/A
Completed	`NCT00944554` - Relapse Prevention With Varenicline	Phase 4
Terminated	`NCT02247258` - Azathioprine in the Prevention of Ileal Crohn's Disease Postoperative Recurrence.	Phase 2
Completed	`NCT03654209` - Post-resection Treatment of Large Colon Polyps	N/A
Recruiting	`NCT05557474` - Development and Clinical Validation of Early-stage Lung Cancer Prognostic Kit
Active, not recruiting	`NCT03865537` - Cold Snare Endoscopic Mucosal Resection Trial	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms